Newstral
David Rind
- Psychedelics Are Challenging the Scientific Gold StandardThe Atlantic
- Agony over ecstasy: FDA bid shows it’s hard to test psychedelicspressherald.com
- KThe real costs of the new Alzheimer’s drug, most of which will fall to taxpayers - Sun, 13 Aug 2023 PSTkffhealthnews.org
- The real costs of the new Alzheimer’s drug, most of which will fall to taxpayersMerced Sun-Star
- CExplicación de los riesgos y beneficios de Leqembi, el nuevo medicamento contra el Alzheimerconsumerreports.org
- Diabetes Drug Mounjaro Expected To Be Approved For Weight Loss Soon: What To Know And How It Compares To Similar DrugsForbes
- Weight-loss drug Tirzepatide is said to be even more effective than OzempicNew York Post
- Exciting new weight loss drugs may also lighten your walletoregonlive.com
- With America's attention on COVID-19, drugmakers are raising US prices across the boarddispatch.com
- MSarepta’s surprise FDA approval for rare disease drug excites investorsmarketwatch.com
- Resolving Tension Between Cost-Effectiveness Analysis And Patient CentricityForbes
- F.D.A. Approves First Drug Designed to Prevent MigrainesThe New York Times
- For $14,000 a year, cholesterol drug fights heart attacksdailynews.com
Frequent names
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.